AlloVir, Inc. (ALVR)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

139 MAIN STREET, SUITE 500 CAMBRIDGE, MA 02142

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Data as of 2021-06-19 12:54:48 -0400
Market Cap1.294 Billion Shares Outstanding65.107 Million Avg 30-day Volume285.126 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-10.17 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low48.96 / 18.15 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ALVR instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 73 71 2.82% 22 (1.29%) 17 (0.99%) 29.41%
13F shares: 26.647 Million 23.404 Million 13.86% 7.817 Million 7.597 Million 2.89%
% Ownership 40.9281 35.9472 13.86% 12.0064 11.6689 2.89%
New Positions: 12 22 -45.45% 5 2 150.0%
Increased Positions 38 24 58.33% 8 5 60.0%
Closed Positions 10 12 -16.67% 6
Reduced Positions 11 14 -21.43% 4 5 -20.0%
Total Calls 200.239 Thousand 5 4004680.0% 200.238 Thousand
Total Puts 19 2 850.0%
PUT/CALL Ratio 0.0 0.4 -100.0% 0.0 -100.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ALVR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALVR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

150 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HALLAL DAVID

  • Director
  • 10% Owner
22,500 2021-05-25 2

WILSON JOHN ROBERT

  • Director
5,385,453 2021-05-25 3

BRENNER MALCOLM

  • Director
186,232 2021-05-25 6

VERA JUAN

  • Director
22,500 2021-05-25 5

BORNSTEIN JEFFREY S

  • Director
22,500 2021-05-25 2

JOVAN-EMBIRICOS MORANA

  • Director
  • 10% Owner
22,500 2021-05-25 1

GADICKE ANSBERT

  • Director
  • 10% Owner
22,500 2021-05-25 1

BRAINARD DIANA CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
706,300 2021-05-17 1

LEEN ANN M. CHIEF SCIENTIFIC OFFICER

  • Officer
2,337,142 2021-05-10 7

MELIAN AGUSTIN CHIEF MEDICAL OFFICER

  • Officer
516,516 2021-03-22 3

MILLER EDWARD GENERAL COUNSEL

  • Officer
386,862 2021-03-01 2

VAN BEEK JEROEN B CHIEF COMMERCIAL OFFICER

  • Officer
488,230 2021-03-01 6

HAGEN BRETT R CHIEF ACCOUNTING OFFICER

  • Officer
64,765 2021-02-22 4

SINHA VIKAS SEE REMARKS

  • Officer
  • Director
14,286,377 2021-01-19 1

ATILLASOY ERCEM SEE REMARKS

  • Officer
106,500 2021-01-19 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WILSON JOHN ROBERT - Director

2021-05-27 16:50:42 -0400 2021-05-25 A 22,500 a 22,500 direct

JOVAN-EMBIRICOS MORANA - Director - > 10% Owner

2021-05-27 16:45:41 -0400 2021-05-25 A 22,500 a 22,500 direct

BRENNER MALCOLM - Director see footnote

2021-05-27 16:50:14 -0400 2021-05-25 G 818,663 d 0 indirect -2.3038 4.0956 4.0956 6 -2.3038 2

GADICKE ANSBERT - Director - > 10% Owner

2021-05-27 16:57:21 -0400 2021-05-25 A 22,500 a 22,500 direct

VERA JUAN - Director

2021-05-27 16:47:14 -0400 2021-05-25 A 22,500 a 22,500 direct

BORNSTEIN JEFFREY S - Director

2021-05-27 16:47:50 -0400 2021-05-25 A 22,500 a 22,500 direct

HALLAL DAVID - Director - > 10% Owner

2021-05-27 16:54:59 -0400 2021-05-25 A 22,500 a 22,500 direct

BRENNER MALCOLM - Director

2021-05-27 16:50:14 -0400 2021-05-25 A 22,500 a 22,500 direct

BRAINARD DIANA - Director - Officer CHIEF EXECUTIVE OFFICER

2021-05-18 17:08:55 -0400 2021-05-17 A 170,000 a 206,300 direct 5.161 8.2386 8.2386 6 0.0 1

BRAINARD DIANA - Director - Officer CHIEF EXECUTIVE OFFICER

2021-05-18 17:08:55 -0400 2021-05-17 A 30,000 a 36,300 direct 5.161 8.2386 8.2386 6 0.0 1

BRAINARD DIANA - Director - Officer CHIEF EXECUTIVE OFFICER

2021-05-18 17:08:55 -0400 2021-05-17 A 500,000 a 500,000 direct

LEEN ANN M. - Officer CHIEF SCIENTIFIC OFFICER see footnote

2021-05-10 17:28:16 -0400 2021-05-10 S 150,000 $22.75 d 2,309,142 indirect -0.876 -2.2339 5.1248 4 -2.2339 6

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ALLOVIR INC ALVR 2021-06-21 22:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 21:45:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 21:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 20:45:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 20:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 19:45:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 19:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 18:45:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 18:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 17:45:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 17:15:03 UTC -0.3699 0.4499 25000
ALLOVIR INC ALVR 2021-06-21 16:45:02 UTC -0.3822 0.4622 25000
ALLOVIR INC ALVR 2021-06-21 16:15:03 UTC -0.3822 0.4622 25000
ALLOVIR INC ALVR 2021-06-21 15:45:03 UTC -0.3822 0.4622 25000
ALLOVIR INC ALVR 2021-06-21 15:15:03 UTC -0.3822 0.4622 25000
ALLOVIR INC ALVR 2021-06-21 14:45:03 UTC -0.41 0.49 25000
ALLOVIR INC ALVR 2021-06-21 14:15:02 UTC -0.41 0.49 25000
ALLOVIR INC ALVR 2021-06-21 13:45:03 UTC -0.41 0.49 25000
ALLOVIR INC ALVR 2021-06-21 13:15:03 UTC -0.41 0.49 25000
ALLOVIR INC ALVR 2021-06-21 12:45:03 UTC -0.41 0.49 25000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments